- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Gandara on the Utility of TMB in NSCLC
July 23rd 2020, 9:45pm
International Lung Cancer Congress
David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.
Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Cancer
July 17th 2020, 10:42pm
International Congress on the Future of Breast Cancer East
Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.
Dr. Mamounas on Recurrence Rates in Breast Cancer
July 17th 2020, 9:38pm
International Congress on the Future of Breast Cancer East
Terry P. Mamounas, MD, MPH, FACS, discusses common recurrence rates in breast cancer.
Key Data Inform Treatment Decisions in Early HER2+ Breast Cancer
July 17th 2020, 9:00pm
International Congress on the Future of Breast Cancer East
The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer
July 17th 2020, 8:50pm
International Congress on the Future of Breast Cancer East
Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.
Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach
July 17th 2020, 8:15pm
International Congress on the Future of Breast Cancer East
The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.
Carving Out New Combination Therapies in Stem Cell Disorders
July 13th 2020, 8:28pm
Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.
Rini Reviews Key ASCO 2020 Highlights in Genitourinary Cancers
July 13th 2020, 2:04pm
As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.
Experts Explore Treatment Approaches With Novel Agents in ALL
July 11th 2020, 9:12pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
A panel of experts in acute lymphoblastic leukemia broach the topic of innovative approaches incorporating novel agents in clinical practice.
Panel of Experts Cover Clinical Scenarios in AML
July 11th 2020, 7:44pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
A panel of experts in acute myeloid leukemia (AML) consider potential treatment options for patients with AML
CML Experts Consider Challenging Cases Faced in Clinical Practice
July 11th 2020, 6:45pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
A panel of experts in chronic myeloid leukemia share insight on how to optimally approach treatment based on patient characteristics.
Dr. Raje on Key Challenges Faced in Multiple Myeloma
July 11th 2020, 6:20pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.
Dr. Leslie on Remaining Questions to Address in MCL
July 11th 2020, 6:18pm
PER® Annual Live Medical Crossfire: Hematologic Malignancies
Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.
Postow Presents Progress Made in Melanoma
July 10th 2020, 9:47pm
Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.
Singal Speaks to ASCO Highlights in Rapidly Evolving HCC Paradigm
July 10th 2020, 6:29pm
The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.
ASCO 2020 Heralds a Handful of Influential Data Across Breast Cancer Settings
July 10th 2020, 5:30pm
The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.
Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC
July 3rd 2020, 3:45pm
ESMO Gastrointestinal Cancers Congress
Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.
Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma
July 3rd 2020, 3:15pm
ESMO Gastrointestinal Cancers Congress
Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.
Wainberg Weighs in on Favorable Frontline Activity With NALIRIFOX Regimen in Pancreatic Cancer
July 3rd 2020, 3:15pm
ESMO Gastrointestinal Cancers Congress
Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.
EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors
July 3rd 2020, 3:00pm
ESMO Gastrointestinal Cancers Congress
EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.